Alto Neuroscience taps CNS expert Raymond Sanchez as director as Phase 2b trial approaches

Alto appoints Dr. Raymond Sanchez to BOD - BioTuesdays

Alto Neuroscience (NYSE: ANRO) has announced the appointment of industry veteran Raymond Sanchez, MD, to its board of directors (BOD), effective August 12, 2025. Dr. Sanchez brings extensive experience in medicine and life sciences to the role, and has served as a senior advisor at Bain Capital Life Sciences since September 2024. Amit Etkin, MD, PhD, founder and CEO of Alto, remarked, “We are delighted to welcome Ray to our BOD as we continue ad…

Alto Neuroscience taps CNS expert Raymond Sanchez as director as Phase 2b trial approaches

Former Cerevel CMO and Yale psychiatrist joins Alto's board as the company prepares for pivotal Phase 2b trial of ALTO-207 in precision psychiatry. Learn more about the strategic move.